(Q53577573)

15 May 2018

title

Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. (English)

1 reference

15 May 2018

0 references

1 reference

1 reference

Mahmood Jeddi-Tehrani

3

1 reference

15 May 2018

Fatemeh Atyabi

8

object named as

Fatemeh Atyabi

1 reference

15 May 2018

Reyhaneh Varshochian

1

1 reference

15 May 2018

Mohammad Riazi-Esfahani

2

1 reference

15 May 2018

Ahmad-Reza Mahmoudi

4

1 reference

15 May 2018

Sara Aghazadeh

5

1 reference

15 May 2018

Mirgholamreza Mahbod

6

1 reference

15 May 2018

Morteza Movassat

7

1 reference

15 May 2018

Araz Sabzevari

9

1 reference

15 May 2018

Rassoul Dinarvand

10

1 reference

15 May 2018

publication date

27 March 2015

1 reference

15 May 2018

Journal of Biomedical Materials Research Part A

published in

1 reference

15 May 2018

volume

103

1 reference

15 May 2018

issue

10

1 reference

15 May 2018

page(s)

3148-3156

1 reference

15 May 2018

Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Molecular pathology of age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Ocular neovascularization: basic mechanisms and therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Recent advances in ocular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

PLGA-based nanoparticles: an overview of biomedical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Protein instability in poly(lactic-co-glycolic acid) microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Distribution and deposition of respirable PLGA microspheres in lung alveoli

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Drug delivery systems for vitreoretinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

Effect of particle size of polymeric nanospheres on intravitreal kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJBM.A.35446

21 January 2018

Identifiers

DOI

10.1002/JBM.A.35446

1 reference

15 May 2018

1 reference

15 May 2018